Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare ConferenceGlobeNewsWire • 03/05/24
Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue EstimatesZacks Investment Research • 02/29/24
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 02/28/24
Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREEGlobeNewsWire • 02/27/24
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical's VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal NeurologyGlobeNewsWire • 02/21/24
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024GlobeNewsWire • 02/14/24
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-TermZacks Investment Research • 01/18/24
Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-TermZacks Investment Research • 01/12/24
Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common StockGlobeNewsWire • 01/05/24
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common StockGlobeNewsWire • 01/04/24
Is Catalyst Pharmaceuticals (CPRX) Stock a Solid Choice Right Now?Zacks Investment Research • 01/02/24
Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo PharmaGlobeNewsWire • 12/18/23